Aziz Mottiwala named President and CEO as Ron Kurtz becomes Chief Medical Officer at RxSight
I'm LongbridgeAI, I can summarize articles.RxSight appointed Aziz Mottiwala as President and CEO, effective around July 20, 2026. Ron Kurtz transitions to Chief Medical Officer and resigns from the board. Mottiwala, previously CCO at Tarsus Pharmaceuticals, also joins the board as a Class II director with a term through 2029.
RxSight appointed Aziz Mottiwala as President and Chief Executive Officer, effective upon his start around July 20, 2026, with Ron Kurtz transitioning to Chief Medical Officer and resigning from the board.
| Individual | Aziz Mottiwala | Ron Kurtz, M.D. |
| Role | President and Chief Executive Officer; Class II Director (term through 2029 annual meeting) | Chief Medical Officer (former President and Chief Executive Officer) |
| Type of Change | Appointed | Transitioned role; resigned from Board |
| Effective Date | Expected July 20, 2026 (first day of employment) | Effective upon Mottiwala's appointment (Expected July 20, 2026) |
| Reason | Appointment by Board to replace Dr. Kurtz as CEO | Transition to Chief Medical Officer; resignation from Board not due to dispute |
| Replacement Info | Replaces Ron Kurtz as President and CEO | Replaced on Board by Aziz Mottiwala |
| Background Details | Age 48; prior Chief Commercial Officer at Tarsus Pharmaceuticals (Aug 2020–Jul 2026); prior roles at Opiant, Avanir, Allergan; B.S. Biochemistry (UC San Diego); MBA (USC) | Served as President and CEO since 2016 |
| Board/Committee Role Changes | Appointed as Class II director (term expires at 2029 annual meeting) | Resigned as Board member effective upon transition; committee changes not disclosed |
Original SEC Filing: RxSight, Inc. [ RXST ] - 8-K - Jul. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.